rs5015480 — HHEX HHEX/IDE locus variant

Regulatory variant near HHEX and IDE linked to impaired beta-cell development and insulin secretion, one of the earliest and most-replicated T2D GWAS loci

See your personal result for HHEX

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HHEX/IDE — The Beta-Cell Blueprint Variant

When scientists began systematically scanning the human genome for type 2 diabetes risk, one of the first and most consistently replicated signals landed on chromosome 10q23 — near two genes with seemingly different jobs: HHEX11 HHEX
Hematopoietically Expressed Homeobox — a transcription factor that acts as a master switch for organ development, including the pancreas and IDE22 IDE
Insulin-Degrading Enzyme — a metalloprotease that degrades insulin and amyloid beta peptides. The SNP rs5015480 sits in this locus and is in complete linkage disequilibrium (r² = 1) with the primary association marker rs1111875, meaning the two variants are inherited together as a single functional unit in nearly all human populations.

The Mechanism

HHEX encodes a homeodomain transcription factor expressed in the liver, thyroid, and — critically — the developing pancreas. During embryogenesis, HHEX is required for proper formation of the ventral pancreatic bud; mice with HHEX knockout fail to develop a normal pancreas and show profound defects in insulin-producing beta-cell mass. In adult beta cells, HHEX continues to regulate genes involved in beta-cell identity and function, including insulin gene expression programs.

The C allele at rs5015480 (and the linked C allele at rs1111875) is associated with reduced HHEX expression in pancreatic tissue, which translates into diminished beta-cell function and reduced first-phase insulin secretion in response to glucose. IDE, located nearby, degrades secreted insulin — variants that alter IDE expression or activity could further modulate circulating insulin levels, though whether IDE or HHEX is the causal gene remains an active area of investigation.

The Evidence

This locus was identified simultaneously by multiple landmark GWAS in 2007, cementing its status as one of the most robustly replicated T2D signals in the literature.

The Sladek et al. 2007 GWAS33 Sladek et al. 2007 GWAS
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007 tested 392,935 SNPs in a French case-control cohort and identified the IDE-KIF11-HHEX locus as one of four novel T2D risk regions, together with TCF7L2 replication.

The Scott et al. 2007 FUSION study44 Scott et al. 2007 FUSION study
Scott LJ et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007 confirmed HHEX among validated T2D susceptibility loci. Combined analysis across the FUSION, DGI, and WTCCC/UKT2D cohorts yielded an odds ratio of 1.13 (95% CI 1.09–1.17)55 1.13 (95% CI 1.09–1.17)
Scott LJ et al. Science, 2007 per C allele (p = 5.7 × 10⁻¹⁰), with a risk allele frequency of ~0.52 in controls. The effect is modest but genome-wide significant and highly reproducible across European, East Asian, and other populations.

Zeggini et al. 200866 Zeggini et al. 2008
Zeggini E et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet, 2008 placed HHEX/IDE among 10 established T2D loci, each conferring allelic odds ratios in the 1.1–1.2 range.

Takeuchi et al. 200977 Takeuchi et al. 2009
Takeuchi F et al. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes, 2009 confirmed the HHEX association in a Japanese cohort, demonstrating the cross-ethnic stability of this signal. Notably, the T allele (the protective variant) is far more common in East Asian populations (~82% frequency vs ~42% in Europeans), which may partly explain differences in T2D genetic architecture across ancestries.

Practical Implications

The HHEX/IDE locus acts primarily through the insulin secretion axis — specifically impaired beta-cell development and reduced first-phase insulin release. Unlike variants that primarily affect insulin resistance (PPARG, ADIPOQ), HHEX risk carriers have beta cells that are constitutively less efficient at responding to a glucose load.

The single most actionable implication is protecting beta-cell reserve through dietary patterns that minimize demand on the insulin secretory apparatus. This means limiting glycemic spikes — not through generic "healthy eating" but through specifically timed, lower-glycemic-index meal patterns that match the reduced first-phase insulin capacity of HHEX C-allele carriers.

Post-meal glucose monitoring and periodic HbA1c checks are particularly informative for this genotype, because the impaired first-phase insulin response is precisely what blunts early post-meal glucose suppression and progressively loads beta-cell reserve over decades.

Interactions

HHEX rs5015480 operates through the insulin secretion pathway, distinct from the insulin resistance pathway. Carrying risk alleles at both this locus (impaired secretion) and at TCF7L2 rs7903146 (impaired Wnt-mediated beta-cell function) compounds T2D risk through converging but independent mechanisms. Similarly, co-inheritance with SLC30A8 rs13266634 (zinc transporter affecting insulin granule crystallization) further loads the insulin secretion pathway. Individuals with risk alleles at multiple secretion- pathway loci should give highest priority to metabolic monitoring and glycemic-load management.

Nutrient Interactions

carbohydrate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Genotype Normal

Two protective alleles — full beta-cell reserve, lowest HHEX-linked T2D risk

You carry two copies of the T allele at the HHEX/IDE locus, which is associated with normal HHEX expression and full beta-cell secretory capacity. This is the minority genotype globally (~18% of people), but is much more common in East Asian populations (~68% TT frequency) than in Europeans (~18%).

Your genotype at this locus does not reduce first-phase insulin secretion — your beta cells are not disadvantaged by the HHEX pathway. This is the lowest-risk configuration for T2D at this locus.

CT Intermediate Risk Intermediate

One risk allele — modestly reduced beta-cell reserve

The heterozygous CT state places you in the middle of the HHEX expression spectrum. One functional (T allele) copy partially compensates for the reduced-expression C allele. The combined GWAS evidence — from the FUSION, DGI, and WTCCC/UKT2D cohorts encompassing tens of thousands of participants — consistently places the per-C-allele OR at ~1.13 (p = 5.7 × 10⁻¹⁰), meaning CT carriers have an approximately 13% higher relative risk of T2D compared to TT homozygotes.

In practical terms, your beta cells respond less briskly to a glucose load in the first few minutes after a meal — the first-phase insulin spike is blunted. Over years of high glycemic load, this can progressively reduce beta-cell reserve.

CC Elevated Risk High Risk

Two risk alleles — reduced HHEX expression, impaired beta-cell function

Two copies of the C allele produce the maximal reduction in HHEX transcript levels in beta cells. The mechanistic consequence is a smaller, slower first-phase insulin pulse, leaving blood glucose suppression to lag in the first 30 minutes after a meal. Over years and decades, this chronically elevated post-meal glucose drives beta-cell exhaustion and insulin resistance more rapidly than in TT or CT individuals.

The HHEX/IDE locus is one of the 10 established T2D susceptibility loci confirmed in the Zeggini et al. 2008 meta-analysis, with a genome-wide-significant signal replicated across European, East Asian, and South Asian populations. East Asian populations rarely carry the CC genotype (~3%) because the T allele runs at ~82% frequency there — a striking population difference that makes this particularly important to track in European and South Asian individuals.

Because the impairment is in secretion (not sensitivity), it compounds multiplicatively with insulin resistance risk variants like PPARG Pro12Ala. An individual with impaired secretion AND impaired sensitivity faces a double-barreled deficit: less insulin produced, and less effect per unit produced.